Search

Your search keyword '"Fabbiano F"' showing total 215 results
Start Over Author "Fabbiano F"
215 results on '"Fabbiano F"'

1. Differences among young adults, adults and elderly chronic myeloid leukemia patients

Author

Salvi, F., Pini, M., Leoni, P., Rupoli, S., Galieni, P., Bigazzi, C., Cantore, N., Palmieri, F., Albano, F., Russo Rossi, A., Rambaldi, A., Intermesoli, T., Palandri, F., Testoni, N., Luatti, S., Soverini, S., Iacobucci, I., Bochicchio, M.T., Apolinari, M., Fogli, M., Cervello, I., Capucci, A., Malagola, M., Malpignano, A., Girasoli, M., Angelucci, E., Usala, E., Storti, S., De Biasi, E., Tagariello, G., Sartori, R., Di Raimondo, F., Vigneri, P., Impera, S., Molica, S., Lanza, F., Viganò, C., Grasso, M., Rapezzi, D., Cavazzini, F., Bosi, A., Santini, V., Capalbo, S.F., Spinosa, G., Pierri, I., Bergamaschi, M., Carella, A.M., Bacigalupo, A., De Blasio, A., Ciccone, F., Di Renzo, N., Musolino, C., Russo, S., Cortelezzi, A., Morra, E., Pungolino, E.M., Luppi, M., Marasca, R., Pogliani, E.M., Gambacorti-Passerini, C., Luciano, L., Ferrara, F., Annunziata, M., Latte, G., Noli, D., Rege-Cambrin, G., Fava, C., Semenzato, G., Binotto, G., Fabbiano, F., Turri, D., Siragusa, S., Caracciolo, C., Musso, M., Porretto, F., Aversa, F., Crugnola, M., Cazzola, M., Orlandi, E., Falini, B., Falzetti, F., Visani, G., Isidori, A., Fioritoni, G., Di Lorenzo, R., Vallisa, D., Trabacchi, E., Petrini, M., Galimberti, S., Pizzuti, M., Zaccaria, A., Salvucci, M., Ronco, F., Ielo, D., Merli, F., Avanzini, P., Tosi, P., Merli, A., Musto, P., De Stefano, V., Sica, S., Latagliata, R., De Fabritiis, P., Trawiska, M., Majolino, I., Pacilli, L., Ronci, B., Cedrone, M., Petti, M.C., Pisani, F., Tafuri, A., Montefusco, E., Iuliano, F., Dore, F., Pardini, S., Bocchia, M., Defina, M., Liberati, A.M., Luzzi, D., Boccadoro, M., Ferrero, D., Vitolo, U., Gherlinzoni, F., Calistri, E., Fanin, R., Pizzolo, G., Meneghini, V., Rodighiero, F., D'Emilio, A., Castagnetti, F., Gugliotta, G., Baccarani, M., Breccia, M., Specchia, G., Levato, L., Abruzzese, E., Rossi, G., Iurlo, A., Martino, B., Pregno, P., Stagno, F., Cuneo, A., Bonifacio, M., Gobbi, M., Russo, D., Gozzini, A., Tiribelli, M., de Vivo, A., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., and Rosti, G.

Published
2015
Full Text
View/download PDF

2. P353: FORTY MONTHS UPDATE OF THE GIMEMA LAL2116 (D-ALBA) PROTOCOL AND ANCILLARY LAL2217 STUDY FOR NEWLY DIAGNOSED ADULT PH+ ALL

Author

Chiaretti, S., primary, Bassan, R., additional, Vitale, A., additional, Elia, L., additional, Piciocchi, A., additional, Viero, P., additional, Ferrara, F., additional, Lunghi, M., additional, Fabbiano, F., additional, Bonifacio, M., additional, Fracchiolla, N., additional, Di Bartolomeo, P., additional, Fazi, P., additional, De Propris, M. S., additional, Vignetti, M., additional, Guarini, A., additional, Rambaldi, A., additional, and Foà, R., additional

Published
2022
Full Text
View/download PDF

3. INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph1 acute lymphoblastic leukemia

Author

Martinelli, G., Papayannidis, C., Piciocchi, A., Robustelli, V., Soverini, S., Terragna, C., Marconi, G., Lemoli, R. M., Guolo, F., Fornaro, A., Lunghi, M., de Fabritiis, P., Candoni, A., Selleri, C., Simonetti, F., Bocchia, M., Vitale, A., Frison, L., Tedeschi, A., Cuneo, A., Bonifacio, M., Martelli, M. P., D'Ardia, S., Trappolini, S., Tosi, P., Galieni, P., Fabbiano, F., Abbenante, M. C., Granier, M., Zhu, Z., Wang, M., Sartor, C., Paolini, S., Cavo, M., Foa, R., Fazi, P., Vignetti, M., and Baccarani, M.

Published
2022

4. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial

Author

Cicconi, L, Platzbecker, U, Avvisati, G, Paoloni, F, Thiede, C, Vignetti, M, Fazi, P, Ferrara, F, Divona, M, Albano, F, Efficace, F, Sborgia, M, Di Bona, E, Breccia, M, Borlenghi, E, Cairoli, R, Rambaldi, A, Melillo, L, La Nasa, G, Fiedler, W, Brossart, P, Hertenstein, B, Salih, H, Annibali, O, Wattad, M, Lubbert, M, Brandts, C, Hanel, M, Rollig, C, Schmitz, N, Lin, H, Frairia, C, Fozza, C, Maria D’Arco, A, Di Renzo, N, Cortelezzi, A, Fabbiano, F, Dohner, K, Ganser, A, Dohner, H, Amadori, S, Mandelli, F, Teresa Voso, M, Ehninger, G, Schlenk, R, Lo-Coco, F, Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Annibali O, Wattad M, Lubbert M, Brandts C, Hanel M, Rollig C, Schmitz N, Lin H, Frairia C, Fozza C, Maria D’Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Teresa Voso M, Ehninger G, Schlenk RF, Lo-Coco F., Cicconi, L, Platzbecker, U, Avvisati, G, Paoloni, F, Thiede, C, Vignetti, M, Fazi, P, Ferrara, F, Divona, M, Albano, F, Efficace, F, Sborgia, M, Di Bona, E, Breccia, M, Borlenghi, E, Cairoli, R, Rambaldi, A, Melillo, L, La Nasa, G, Fiedler, W, Brossart, P, Hertenstein, B, Salih, H, Annibali, O, Wattad, M, Lubbert, M, Brandts, C, Hanel, M, Rollig, C, Schmitz, N, Lin, H, Frairia, C, Fozza, C, Maria D’Arco, A, Di Renzo, N, Cortelezzi, A, Fabbiano, F, Dohner, K, Ganser, A, Dohner, H, Amadori, S, Mandelli, F, Teresa Voso, M, Ehninger, G, Schlenk, R, Lo-Coco, F, Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Annibali O, Wattad M, Lubbert M, Brandts C, Hanel M, Rollig C, Schmitz N, Lin H, Frairia C, Fozza C, Maria D’Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Teresa Voso M, Ehninger G, Schlenk RF, and Lo-Coco F.

Published
2020

6. Differences among young adults, adults and elderly chronic myeloid leukemia patients

Author

Castagnetti, F., Gugliotta, G., Baccarani, M., Breccia, M., Specchia, G., Levato, L., Abruzzese, E., Rossi, G., Iurlo, A., Martino, B., Pregno, P., Stagno, F., Cuneo, A., Bonifacio, M., Gobbi, M., Russo, D., Gozzini, A., Tiribelli, M., de Vivo, A., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., Rosti, G., Salvi, F., Pini, M., Leoni, P., Rupoli, S., Galieni, P., Bigazzi, C., Cantore, N., Palmieri, F., Albano, F., Russo Rossi, A., Rambaldi, A., Intermesoli, T., Palandri, F., Testoni, N., Luatti, S., Soverini, S., Iacobucci, I., Bochicchio, MT., Apolinari, M., Fogli, M., Cervello, I., Capucci, A., Malagola, M., Malpignano, A., Girasoli, M., Angelucci, E., Usala, E., Storti, S., De Biasi, E., Tagariello, G., Sartori, R., Di Raimondo, F., Vigneri, P., Impera, S., Molica, S., Lanza, F., Viganò, C., Grasso, M., Rapezzi, D., Cavazzini, F., Bosi, A., Santini, V., Capalbo, SF., Spinosa, G., Pierri, I., Bergamaschi, M., Carella, AM., Bacigalupo, A., De Blasio, A., Ciccone, F., Di Renzo, N., Musolino, C., Russo, S., Cortelezzi, A., Morra, E., Pungolino, EM., Luppi, M., Marasca, R., Pogliani, EM., Gambacorti-Passerini, C., Luciano, L., Ferrara, F., Annunziata, M., Latte, G., Noli, D., Rege-Cambrin, G., Fava, C., Semenzato, G., Binotto, G., Fabbiano, F., Turri, D., Siragusa, S., Caracciolo, C., Musso, M., Porretto, F., Aversa, F., Crugnola, M., Cazzola, M., Orlandi, E., Falini, B., Falzetti, F., Visani, G., Isidori, A., Fioritoni, G., Di Lorenzo, R., Vallisa, D., Trabacchi, E., Petrini, M., Galimberti, S., Pizzuti, M., Zaccaria, A., Salvucci, M., Ronco, F., Ielo, D., Merli, F., Avanzini, P., Tosi, P., Merli, A., Musto, P., De Stefano, V., Sica, S., Latagliata, R., De Fabritiis, P., Trawiska, M., Majolino, I., Pacilli, L., Ronci, B., Cedrone, M., Petti, MC., Pisani, F., Tafuri, A., Montefusco, E., Iuliano, F., Dore, F., Pardini, S., Bocchia, M., Defina, M., Liberati, AM., Luzzi, D., Boccadoro, M., Ferrero, D., Vitolo, U., Gherlinzoni, F., Calistri, E., Fanin, R., Pizzolo, G., Meneghini, V., Rodighiero, F., and DʼEmilio, A.

Published
2015
Full Text
View/download PDF

7. MULTI-GENOTYPING OF MINOR HISTOCOMPATIBILITY ANTIGENS (MHAGS) IN ALLOGENEIC STEM CELL TRANSPLANTATION AND THEIR ROLE IN DETERMINING GRAFT VERSUS HOST DISEASE (GVHD) AND GRAFT VERSUS LEUKEMIA (GVL) EFFECT: PH-P109

Author

Cattina, F., Skert, C., Bernardi, S., Malagola, M., Ottaviani, E., Bochicchio, M. T., Iacobucci, I., Soverini, S., Bonifazi, F., Bandini, G., Arpinati, M., Motta, M. R., Toffoletti, E., Damiani, D., Santoro, A., Fabbiano, F., Pastore, D., Specchia, G., Console, G., Bruno, M., Carella, G., Malagoli, A., Guadagnuolo, V., De Benedittis, C., Bergonzi, C., Filì, C., Turra, A., Ribolla, R., Cancelli, V., Alghisi, E., Perucca, S., Di Palma, A., Martinelli, G., and Russo, D.

Published
2014

8. VERY LONG-TERM RESULTS OF ALL-TRANS RETINOIC ACID AND ARSENIC TRIOXIDE IN NON-HIGH RISK ACUTE PROMYELOCYTIC LEUKEMIA: LATEST UPDATE OF THE ITALIAN-GERMAN APL0406 RANDOMIZED TRIAL

Author

Cicconi, L, Platzbecker, U, Avvisati, G, Paoloni, F, Thiede, C, Vignetti, M, Fazi, P, Ferrara, F, Divona, M, Albano, F, Efficace, F, Sborgia, M, Di Bona, E, Breccia, M, Borlenghi, E, Cairoli, R, Rambaldi, A, Melillo, L, La Nasa, G, Fiedler, W, Brossart, P, Hertenstein, B, Salih, H, Annibali, O, Wattad, M, Lubbert, M, Brandts, C, Hanel, M, Rollig, C, Schmitz, N, Lin, H, Frairia, C, Fozza, C, Maria D’Arco, A, Di Renzo, N, Cortelezzi, A, Fabbiano, F, Dohner, K, Ganser, A, Dohner, H, Amadori, S, Mandelli, F, Teresa Voso, M, Ehninger, G, Schlenk, R, Lo-Coco, F, Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Annibali O, Wattad M, Lubbert M, Brandts C, Hanel M, Rollig C, Schmitz N, Lin H, Frairia C, Fozza C, Maria D’Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Teresa Voso M, Ehninger G, Schlenk RF, Lo-Coco F., Cicconi, L, Platzbecker, U, Avvisati, G, Paoloni, F, Thiede, C, Vignetti, M, Fazi, P, Ferrara, F, Divona, M, Albano, F, Efficace, F, Sborgia, M, Di Bona, E, Breccia, M, Borlenghi, E, Cairoli, R, Rambaldi, A, Melillo, L, La Nasa, G, Fiedler, W, Brossart, P, Hertenstein, B, Salih, H, Annibali, O, Wattad, M, Lubbert, M, Brandts, C, Hanel, M, Rollig, C, Schmitz, N, Lin, H, Frairia, C, Fozza, C, Maria D’Arco, A, Di Renzo, N, Cortelezzi, A, Fabbiano, F, Dohner, K, Ganser, A, Dohner, H, Amadori, S, Mandelli, F, Teresa Voso, M, Ehninger, G, Schlenk, R, Lo-Coco, F, Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Annibali O, Wattad M, Lubbert M, Brandts C, Hanel M, Rollig C, Schmitz N, Lin H, Frairia C, Fozza C, Maria D’Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Teresa Voso M, Ehninger G, Schlenk RF, and Lo-Coco F.

Published
2019

9. IN ADULT ACUTE MYELOID LEUKEMIA (AML) PERIPHERAL BLOOD MEASURABLE RESIDUAL DISEASE (MRD) BY FLOW CYTOMETRY (FC) IS FEASIBLE AND IS PROGNOSTICALLY RELEVANT

Author

Maurillo, L, Buccisano, F, Piciocchi, A, Del Principe, M, Candoni, A, Melillo, L, Calafiore, V, Cairoli, R, De Fabritiis, P, Storti, G, Salutari, P, Lanza, F, Martinelli, G, Luppi, M, Mazza, P, Martelli, M, Cuneo, A, Albano, F, Fabbiano, F, Tafuri, A, Chierichini, A, Tieghi, A, Fracchiolla, N, Capelli, D, Foa, R, Alati, C, La Sala, E, Voso, M, Fazi, P, Vignetti, M, Consalvo, M, Ottone, T, Lavorgna, S, Arcese, W, Lo Coco, F, Amadori, S, Venditti, A, Maurillo L, Buccisano F, Piciocchi A, Del Principe MI, Candoni A, Melillo L, Calafiore V, Cairoli R, De Fabritiis P, Storti G, Salutari P, Lanza F, Martinelli G, Luppi M, Mazza P, Martelli MP, Cuneo A, Albano F, Fabbiano F, Tafuri A, Chierichini A, Tieghi A, Fracchiolla NS, Capelli D, Foa R, Alati C, La Sala E, Voso MT, Fazi P, Vignetti M, Consalvo MI, Ottone T, Lavorgna S, Arcese W, Lo Coco F, Amadori S, Venditti a., Maurillo, L, Buccisano, F, Piciocchi, A, Del Principe, M, Candoni, A, Melillo, L, Calafiore, V, Cairoli, R, De Fabritiis, P, Storti, G, Salutari, P, Lanza, F, Martinelli, G, Luppi, M, Mazza, P, Martelli, M, Cuneo, A, Albano, F, Fabbiano, F, Tafuri, A, Chierichini, A, Tieghi, A, Fracchiolla, N, Capelli, D, Foa, R, Alati, C, La Sala, E, Voso, M, Fazi, P, Vignetti, M, Consalvo, M, Ottone, T, Lavorgna, S, Arcese, W, Lo Coco, F, Amadori, S, Venditti, A, Maurillo L, Buccisano F, Piciocchi A, Del Principe MI, Candoni A, Melillo L, Calafiore V, Cairoli R, De Fabritiis P, Storti G, Salutari P, Lanza F, Martinelli G, Luppi M, Mazza P, Martelli MP, Cuneo A, Albano F, Fabbiano F, Tafuri A, Chierichini A, Tieghi A, Fracchiolla NS, Capelli D, Foa R, Alati C, La Sala E, Voso MT, Fazi P, Vignetti M, Consalvo MI, Ottone T, Lavorgna S, Arcese W, Lo Coco F, Amadori S, and Venditti a.

Published
2019

11. 'Twins Intramedullary Tumors': Case Report of a Double Spinal Metastasis from Breast Cancer. Technical Nuances and Review of the Literature

Author

Fabbiano F, Innocenzi G, Ricciardi F, and Pizzuti

Subjects
medicine.medical_specialty, business.industry, Intramedullary spinal cord, General Medicine, medicine.disease, law.invention, Intramedullary rod, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, law, 030220 oncology & carcinogenesis, Medicine, Spinal metastasis, Radiology, Complication, business, 030217 neurology & neurosurgery
Abstract

Intramedullary spinal cord metastases (ISCMs) represent a rare complication of malignancies and have been identified...

Published
2020
Full Text
View/download PDF

13. VERY LONG-TERM RESULTS OF ALL-TRANS RETINOIC ACID AND ARSENIC TRIOXIDE IN NON-HIGH RISK ACUTE PROMYELOCYTIC LEUKEMIA: LATEST UPDATE OF THE ITALIAN-GERMAN APL0406 RANDOMIZED TRIAL

Author

Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Annibali O, Wattad M, Lubbert M, Brandts C, Hanel M, Rollig C, Schmitz N, Lin H, Frairia C, Fozza C, Maria D’Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Teresa Voso M, Ehninger G, Schlenk RF, Lo-Coco F., Cicconi, L, Platzbecker, U, Avvisati, G, Paoloni, F, Thiede, C, Vignetti, M, Fazi, P, Ferrara, F, Divona, M, Albano, F, Efficace, F, Sborgia, M, Di Bona, E, Breccia, M, Borlenghi, E, Cairoli, R, Rambaldi, A, Melillo, L, La Nasa, G, Fiedler, W, Brossart, P, Hertenstein, B, Salih, H, Annibali, O, Wattad, M, Lubbert, M, Brandts, C, Hanel, M, Rollig, C, Schmitz, N, Lin, H, Frairia, C, Fozza, C, Maria D’Arco, A, Di Renzo, N, Cortelezzi, A, Fabbiano, F, Dohner, K, Ganser, A, Dohner, H, Amadori, S, Mandelli, F, Teresa Voso, M, Ehninger, G, Schlenk, R, and Lo-Coco, F

Subjects
Hematology
Published
2019

14. Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients

Author

Baron, F., Efficace, F., Cannella, L., Willemze, R., Vignetti, M., Muus, P., Marie, J.P., Ferrero, D., Fazi, P., La Sala, E., Bourhis, J.H., Fabbiano, F., Bosi, A., Sborgia, M., Martinelli, G., Wittnebel, S., Trisolini, S., Petti, M.C., Halkes, C.J., Velden, W.J.F.M. van der, Witte, T.J. de, Amadori, S., Zittoun, R.A., Suciu, S., Baron, F., Efficace, F., Cannella, L., Willemze, R., Vignetti, M., Muus, P., Marie, J.P., Ferrero, D., Fazi, P., La Sala, E., Bourhis, J.H., Fabbiano, F., Bosi, A., Sborgia, M., Martinelli, G., Wittnebel, S., Trisolini, S., Petti, M.C., Halkes, C.J., Velden, W.J.F.M. van der, Witte, T.J. de, Amadori, S., Zittoun, R.A., and Suciu, S.

Abstract

Contains fulltext : 218286.pdf (publisher's version ) (Open Access)

Published
2020

15. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: Final results of the randomized Italian-German APL0406 trial

Author

Platzbecker, U, Avvisati, G, Cicconi, L, Thiede, C, Paoloni, F, Vignetti, M, Ferrara, F, Divona, M, Albano, F, Efficace, F, Fazi, P, Sborgia, M, Di Bona, E, Breccia, M, Borlenghi, E, Cairoli, R, Rambaldi, A, Melillo, L, La Nasa, G, Fiedler, W, Brossart, P, Hertenstein, B, Salih, H, Wattad, M, Lübbert, M, Brandts, C, Hänel, M, Röllig, C, Schmitz, N, Link, H, Frairia, C, Pogliani, E, Fozza, C, D'Arco, A, Di Renzo, N, Cortelezzi, A, Fabbiano, F, Döhner, K, Ganser, A, Döhner, H, Amadori, S, Mandelli, F, Ehninger, G, Schlenk, R, Lo-Coco, F, Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F., Platzbecker, U, Avvisati, G, Cicconi, L, Thiede, C, Paoloni, F, Vignetti, M, Ferrara, F, Divona, M, Albano, F, Efficace, F, Fazi, P, Sborgia, M, Di Bona, E, Breccia, M, Borlenghi, E, Cairoli, R, Rambaldi, A, Melillo, L, La Nasa, G, Fiedler, W, Brossart, P, Hertenstein, B, Salih, H, Wattad, M, Lübbert, M, Brandts, C, Hänel, M, Röllig, C, Schmitz, N, Link, H, Frairia, C, Pogliani, E, Fozza, C, D'Arco, A, Di Renzo, N, Cortelezzi, A, Fabbiano, F, Döhner, K, Ganser, A, Döhner, H, Amadori, S, Mandelli, F, Ehninger, G, Schlenk, R, Lo-Coco, F, Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, and Lo-Coco F.

Abstract

Purpose: The initial results of the APL0406 trial showed that the combination of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) is at least not inferior to standard ATRA and chemotherapy (CHT) in first-line therapy of low- or intermediate-risk acute promyelocytic leukemia (APL). We herein report the final analysis on the complete series of patients enrolled onto this trial. Patients and Methods: The APL0406 study was a prospective, randomized, multicenter, open-label, phase III noninferiority trial. Eligible patients were adults between 18 and 71 years of age with newly diagnosed, low- or intermediate-risk APL (WBC at diagnosis ≤ 10 × 109/L). Overall, 276 patients were randomly assigned to receive ATRA-ATO or ATRA-CHT between October 2007 and January 2013. Results: Of 263 patients evaluable for response to induction, 127 (100%) of 127 patients and 132 (97%) of 136 patients achieved complete remission (CR) in the ATRA-ATO and ATRA-CHT arms, respectively (P = .12). After a median follow-up of 40.6 months, the event-free survival, cumulative incidence of relapse, and overall survival at 50 months for patients in the ATRA-ATO versus ATRA-CHT arms were 97.3% v 80%, 1.9% v 13.9%, and 99.2% v 92.6%, respectively (P < .001, P = .0013, and P = .0073, respectively). Postinduction events included two relapses and one death in CR in the ATRA-ATO arm and two instances of molecular resistance after third consolidation, 15 relapses, and five deaths in CR in the ATRA-CHT arm. Two patients in the ATRA-CHT arm developed a therapy-related myeloid neoplasm. Conclusion: These results show that the advantages of ATRA-ATO over ATRA-CHT increase over time and that there is significantly greater and more sustained antileukemic efficacy of ATO-ATRA compared with ATRA-CHT in low- and intermediate-risk APL.

Published
2017

18. S1617 A DASATINIB-BLINATUMOMAB COMBINATION FOR THE FRONT-LINE TREATMENT OF ADULT PH+ ALL PATIENTS. PRELIMINARY RESULTS OF THE GIMEMA LAL2116 D-ALBA TRIAL; ON BEHALF OF GIMEMA ACUTE LEUKEMIA WORKING PARTY

Author

Chiaretti, S., primary, Bassan, R., additional, Vitale, A., additional, Elia, L., additional, Piciocchi, A., additional, Ferrara, F., additional, Lunghi, M., additional, Fabbiano, F., additional, Bonifacio, M., additional, Fracchiolla, N., additional, Salutari, P., additional, Mancino, A., additional, Vignetti, M., additional, Rambaldi, A., additional, and Foà, R., additional

Published
2019
Full Text
View/download PDF

19. S876 GILTERITINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-MUTATED (FLT3MUT+) RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PHASE 3 ADMIRAL TRIAL

Author

Perl, A., primary, Martinelli, G., additional, Cortes, J., additional, Neubauer, A., additional, Berman, E., additional, Paolini, S., additional, Montesinos, P., additional, Baer, M., additional, Larson, R., additional, Ustun, C., additional, Fabbiano, F., additional, Di Stasi, A., additional, Stuart, R., additional, Olin, R., additional, Kasner, M., additional, Ciceri, F., additional, Chou, W.-C., additional, Podoltsev, N., additional, Recher, C., additional, Yokoyama, H., additional, Hosono, N., additional, Yoon, S.-S., additional, Lee, J.-H., additional, Pardee, T., additional, Fathi, A., additional, Liu, C., additional, Liu, X., additional, Bahceci, E., additional, and Levis, M., additional

Published
2019
Full Text
View/download PDF

20. The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes

Author

Malato, A., Dentali, F., Siragusa, S., Fabbiano, F., Kagoma, Y., Boddi, M., Gensini, G., Peris, A., Crowther, M., Napolitano, M., Malato, A., Dentali, F., Siragusa, S., Fabbiano, F., Kagoma, Y., Boddi, M., Gensini, G., Peris, A., Crowther, M., and Napolitano, M.

Subjects
Risk, Critical Illness, Intensive Care Unit, Critically ill patients, Deep vein thrombosis, Meta-analysis, Outcomes, Cohort Studies, Hospital Mortality, Humans, Intensive Care Units, Length of Stay, Pulmonary Embolism, Randomized Controlled Trials as Topic, Research Design, Respiration, Artificial, Thrombophilia, Treatment Outcome, Venous Thrombosis, Hematology, Immunology and Allergy, Review, Deep Vein Thrombosis, Critically Ill Patients, outcomes, metanalysis, Deep vein thrombosi, Meta-analysi, Venous Thrombosi, Outcome, Critical Illne, Critically ill patient, Cohort Studie, Human
Abstract

Background. Critically ill patients appear to be at high risk of developing deep vein thrombosis (DVT) and pulmonary embolism during their stay in the intensive care unit (ICU). However, little is known about the clinical course of venous thromboembolism in the ICU setting. We therefore evaluated, through a systematic review of the literature, the available data on the impact of a diagnosis of DVT on hospital and ICU stay, duration of mechanical ventilation and mortality in critically ill patients. We also tried to determine whether currently adopted prophylactic measures need to be revised and improved in the ICU setting. Materials and methods. MEDLINE and EMBASE databases were searched up to week 4 of June 2012. Two reviewers selected studies and extracted data. Pooled results are reported as relative risks and weighted mean differences and are presented with 95% confidence intervals (CI). Results. Seven studies for a total of 1,783 patients were included. A diagnosis of DVT was frequent in these patients with a mean rate of 12.7% (95% CI: 8.7-17.5%). DVT patients had longer ICU and hospital stays compared to those without DVT (7.28 days; 95% CI: 1.4-13.15; and 11.2 days; 95% CI: 3.82-18.63 days, respectively). The duration of mechanical ventilation was significantly increased in DVT patients (weighted mean difference: 4.85 days; 95% CI: 2.07-7.63). DVT patients had a marginally significant increase in the risk of hospital mortality (relative risk 1.31; 95% CI: 0.99-1.74; p=0.06), and a not statistically significant increase in the risk of ICU mortality (RR 1.64; 95% CI: 0.91-2.93; p=0.10). Conclusions. A diagnosis of DVT upon ICU admission appears to affect clinically important outcomes including duration of ICU and hospital stay and hospital mortality. Larger, prospective studies are warranted.

Published
2015

21. UPREGULATION OF MIR-29A AND GENOMIC DNA HYPERMETHYLATION IN NORMAL KARYOTYPE AML SHOWING DNMT3A MUTATION UPREGOLAZIONE DEL MIR-29A E IPERMETILAZIONE DEL DNA GENOMICO NELLE LAM A CARIOTIPO NORMALE DNMT3A MUTATE

Author

Randazzo V, Agueli C, Salemi, Domenico, Valenti D, Mirto M, Marfia A, Bica MG, Cannella S, Dragotto P, Romano A, La Rosa C, CARADONNA, Fabio, Fabbiano F, Santoro A., Randazzo V, Agueli C, Salemi D, Valenti D, Mirto M, Marfia A, Bica MG, Cannella S, Dragotto P, Romano A, La Rosa C, Caradonna F, Fabbiano F, and Santoro A

Subjects
Settore BIO/18 - Genetica, Acute Myeloid Leukemia, miRNA, Genomewide DNA Methylation
Abstract

DNMT3A, a member of DNA methyltransferases, is mutated in approximately 22% of de novo normal karyotype acute myeloid leukemia (NK-AML) patients leading to adverse overall survival. The highly recurrent mutation in DNMT3A is a “gain of function-like” at codon R882. To indagate about miRNA signature in NK-AML R882-DNMT3A mutated we studied by qRT-PCR the expression of 384 known human miRNA in 9 selected de-novo AML DNMT3A mutated. We compared miRNA expression data with our previous results obtained in 31 AML DNMT3A wild type (WT) and we focused on a strong up-regulation of miR155, miR29a, miR196b and miR25. We consolidated this data in additional 24 new DNMT3A mutated AML and we confirmed the upregulation of miR29a (fold 289,201; p-value 0,000); miR29a has been demonstrated to directly target 3’UTR of DNMT3A resulting in a global hypomethylation but also directly suppress two major DNA demethylases TET1 and TDG. To understand the pathogenesis of the subgroup of AML DNMT3A mutated and the existing correlation between miR29a and its targets, we evaluated the expression levels of miR29a targets DNMT3A, TET1 and TDG in 43 AML DNMT3A mutated patients and in 43 control group AML DNMT3A WT by qRT-PCR. Results obtained revealed a no significant difference in expression of DNMT3A and of TDG; however we found a significant downregulation of the demethylases TET1 (0,661 fold; p-value 0,039). These data suggest that miR29a acts as a crucial regulator of DNA methylation and probably in presence of DNMT3A activating mutations and TET1 downregulation may cause a perturbation of methylation pattern. We analyzed the methylation status of the genomic DNA of bone marrow cells from 6 AML patients (including 3 DNMT3A-mutated and 3 DNMT3A-WT cases) and from 5 healty donors as control by Methylation Sensitive Arbitrarily Primed-PCR that provides a qualitative estimate of genome-wide DNA methylation. Results showed a global hypermethylation of genome in DNMT3A mutated patients compared to DNMT3A WT group and healthy bone marrow. The performed study increasingly suggests that the DNMT3A gain-of-function mutation, the significant upregulation of miR29a and significant downregulation of demethylase TET1 target gene would contribute to the maintenance of the hypermethylation status of the genome in patients with DNMT3A mutation. This issue may have important implications for treatment and response to hypomethylating drugs in patients affected by alterations in DNMT3A.

Published
2015

22. Upregulation of miR-29a and genomic DNA hypermethylation in normal karyotype AML showing DNMT3A mutation

Author

Randazzo V, Agueli C, Salemi D, Valenti D, Mirto M, Marfia A, Bica MG, Cannella S, Fabbiano F, La Rosa C, Caradonna F, Santoro A., Randazzo V, Agueli C, Salemi D, Valenti D, Mirto M, Marfia A, Bica MG, Cannella S, Fabbiano F, La Rosa C, Caradonna F, and Santoro A.

Subjects
Settore BIO/18 - Genetica, Myeloid Acute Leukemia, miRNA, Genomewide DNA methylation
Abstract

Acute Myeloid Leukaemia (AML) is frequently associated to normal karyotype and DNMT3A mutations (R882). Since we previously demonstrated distinctive miRNA expression in some AML groups, we study 384 miRNA in 9 selected DNMT3A-mutated NK-AML patients. Comparing these data with our previous results obtained in 31 DNMT3A-unmutated AML, we focused on a significant up-regulation of miR-155, miR-29a, miR-196b and miR-25. We investigated expression of these miRNAs in additional 24 DNMT3A-mutated AML patients and we confirm the up-regulation of miR-155, miR-29a and miR-196b; in particular, we judged very interesting the over expression of miR-29a since is known to directly target DNMT3A, TET1 and TDG mRNAs. Evaluating the expression levels of these targets in 17 AML DNMT3A-mutated patients, we revealed a no significant differences in expression of DNMT3A and TDG but a significant down-regulation of TET1. These data suggest that miR-29a acts as DNA methylation-regulator: in presence of DNMT3A activating mutations and TET1 down-regulation it may probably cause a perturbation of DNA methylation. In fact, analyzing the methylation of the bone marrow genomic DNA from 3 DNMT3A-mutated and 3 DNMT3A-unmutated cases by Methylation Sensitive Arbitrarily Primed-PCR, we found a genomic hypermethylation of DNMT3A-mutated cells compared to the unmutated ones. How DNMT3A mutations contribute to leukemogenesis is not yet well characterized. Uncovering how DNMT3A mutations affect DNA methylation and epigenetic regulation of gene expression may have important implications in treatment selection because DNA hypomethylating agents are increasingly used in AML therapies, and response to these drugs may be affected by DNMT3A changed function.

Published
2015

23. A population-based study of chronic myeloid leukemia patients treated with imatinib in first line

Author

Castagnetti, F, DI RAIMONDO, Francesco, De Vivo, A, Spitaleri, A, Gugliotta, G, Fabbiano, F, Capodanno, I, Mannina, D, Salvucci, M, Antolino, A, Marasca, R, Musso, M, Crugnola, M, Impera, S, Trabacchi, E, Musolino, C, Cavazzini, F, Mineo, G, Tosi, P, Tomaselli, C, Rizzo, M, Siragusa, S, Fogli, M, Ragionieri, R, Zironi, A, Soverini, S, Martinelli, G, Cavo, M, Vigneri, Paolo, Stagno, F, Rosti, G, Baccarani, M., Castagnetti, Fausto, Di Raimondo, Francesco, De Vivo, Antonio, Spitaleri, Antonio, Gugliotta, Gabriele, Fabbiano, Francesco, Capodanno, Isabella, Mannina, Donato, Salvucci, Marzia, Antolino, Agostino, Marasca, Roberto, Musso, Maurizio, Crugnola, Monica, Impera, Stefana, Trabacchi, Elena, Musolino, Caterina, Cavazzini, Francesco, Mineo, Giuseppe, Tosi, Patrizia, Tomaselli, Carmela, Rizzo, Michele, Siragusa, Sergio, Fogli, Miriam, Ragionieri, Riccardo, Zironi, Alessandro, Soverini, Simona, Martinelli, Giovanni, Cavo, Michele, Vigneri, Paolo, Stagno, Fabio, Rosti, Gianantonio, and Baccarani, Michele

Subjects
Male, Leukemia, Chronic myeloid leukemia, Hematology, Middle Aged, Disease-Free Survival, NO, Hematology, Chronic myeloid leukemia, imatinib, Disease-Free Survival, Female, Humans, Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Male, Middle Aged, Prospective Studies, Protein Kinase Inhibitors, Treatment Outcome, Treatment Outcome, imatinib, Female, Humans, Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Prospective Studies, Protein Kinase Inhibitors, BCR-ABL Positive, Chronic, Myelogenous
Abstract

Chronic myeloid leukemia (CML) treatment is based on company-sponsored and academic trials testing different tyrosine kinase inhibitors (TKIs) as first-line therapy. These studies included patients selected according to many inclusion–exclusion criteria, particularly age and comorbidities, with specific treatment obligations. In daily clinical practice (real-life), inclusion–exclusion criteria do not exist, and the treatment outcome does not only depend on the choice of first-line TKI but also on second- and third-line TKIs. To investigate in a real-life setting the response and the outcome on first-line imatinib, with switch to second generation TKIs in case of unsatisfying response or intolerance, we analyzed all newly diagnosed patients (N = 236), living in two Italian regions, registered in a prospective study according to population-based criteria and treated front-line with imatinib. A switch from imatinib to second-generation TKIs was reported in 14% of patients for side effects and in 24% for failure or suboptimal response, with an improvement of molecular response in 57% of them. The 5-year overall survival (OS) and leukemia-related survival (LRS) were 85% and 93%, respectively; the 4-year rates of MR3.0 and MR4.0 were 75% and 48%, respectively. Cardiovascular complications were reported in 4% of patients treated with imatinib alone and in 6% of patients receiving nilotinib as second-line. Older age (≥70 years) affected OS, but not LRS. These data provide an unbiased reference on the CML management and on the results of TKI treatment in real-life, according to ELN recommendations, using imatinib as first-line treatment and second-generation TKIs as second-line therapy. Am. J. Hematol. 92:82–87, 2017. © 2016 Wiley Periodicals, Inc.

Published
2016

25. How patients perceive a switch from imatinib to nilotinib: results of a patient-centered analysis

Author

Breccia, M., Sorà, F., Annunziata, M., Iovine, M., Caocci, G., Luciano, L., Franceschini, l, Falzetti, F., Morabito, F., Russo Rossi, A., Celesti, F., Scortechini, Ar, Iurlo, A., Bergamaschi, M., Stagno, F., Avanzini, P., Massimiliano BONIFACIO, Binotto, G., Fabbiano, F., Gozzini, A., Pregno, P., Martino, B., Salvucci, M., Cecchini, I., Santis, E., Pennella, A., Rosti, G., and Abruzzese, E.

Subjects
quality of life, Chronic myeloid leukemia, switch, quality of life, Chronic myeloid leukemia, switch
Published
2016

27. TREATMENT, RESPONSE, AND OUTCOME IN UNSELECTED ELDERLY PATIENTS WITH NEWLY DIAGNOSED, CHRONIC PHASE (CP), PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) CHRONIC MYELOID LEUKEMIA

Author

Gugliotta, G, Stagno, F, De Vivo, A, Spitalieri, A, Castagnetti, F, Fabbiano, F, Capodanno, I, Mannina, D, Salvucci, M, Antolino, A, Marasca, R, Musso, M, Crugnola, M, Consoli, U, Trabacchi, E, Musolino, C, Cavazzini, F, Longo, G, Tosi, P, Cardinale, G, Rizzo, M, Soverini, S, Martinelli, G, Cavo, M, Vigneri, Paolo, Rosti, G, DI RAIMONDO, Francesco, and Baccarani, M.

Subjects
Socio-culturale
Published
2016

28. IMATINIB FIRST-LINE WITH SWITCH TO 2ND GENERATION TYROSINE KINASE INHIBITORS IN CASE OF FAILURE OR TOXICITY: REAL-LIFE DATA FROM A POPULATION-BASED REGISTRY OF BCR-ABL1+CML PATIENTS

Author

Castagnetti, F., Stagno, F., de Vivo, A., Spitalieri, A., Gugliotta, G., Fabbiano, F., Capodanno, I., Mannina, D., Salvucci, M., Antolino, A., Marasca, R., Musso, M., Crugnola, M., Consoli, U., Trabacchi, E., Musolino, C., Cavazzini, Francesco, Longo, G., Tosi, P., Cardinale, G., Soverini, S., Rizzo, M., Martinelli, G., Cavo, M., Vigneri, P., Rosti, G., Di Raimondo, F., and Baccarani, M.

Subjects
Socio-culturale
Published
2016

29. Clinico-biologic features of 5202 acute lymphoblastic leukemia patients enrolled in the Italian AIEOP and GIMEMA Protocols and stratified in age-cohorts

Author

Chiaretti, S, Vitale, A, CAZZANIGA, GIOVANNI ITALO, Orlando, S, Silvestri, D, Fazi, P, VALSECCHI, MARIA GRAZIA, Elia, L, Testi, A, MANCINI, FLAVIA, Conter, V, Te Kronnie, G, Ferrara, F, Di Raimondo, F, Tedeschi, A, Fioritoni, G, Fabbiano, F, Meloni, G, Specchia, G, Pizzolo, G, MANDELLI, FABIO, Guarini, A, Basso, G, BIONDI, ANDREA, Foa', R., Chiaretti, S, Vitale, A, Cazzaniga, G, Orlando, S, Silvestri, D, Fazi, P, Valsecchi, M, Elia, L, Testi, A, Mancini, F, Conter, V, Te Kronnie, G, Ferrara, F, Di Raimondo, F, Tedeschi, A, Fioritoni, G, Fabbiano, F, Meloni, G, Specchia, G, Pizzolo, G, Mandelli, F, Guarini, A, Basso, G, Biondi, A, and Foa', R

Subjects
Adult Acute Lymphoblastic Leukemia, Cytogenetics and Molecular Genetics, Immunophenotyping, Pediatric Acute Lymphoblastic Leukemia
Abstract

Acute lymphoblastic leukemia shows marked differences in outcome between children and adults. Since there is limited information on the distribution of clinico-biologic variables in different age cohorts, we analyzed 5202 ALL patients enrolled in the Italian multicenter AIEOP and GIMEMA protocols and stratified them in 9 age cohorts. The highest prevalence of ALL was observed in children, although a second peak was recorded from the 4th decade onwards. Interestingly, the lowest incidence was found in females between 14-40 years, suggesting a protective impact of fertility. Immunophenotypic characterization showed a B-lineage in 85.8% of patients: a pro-B stage, associated to MLL/AF4 positivity, was more frequent in patients between 10-50 years. A T-lineage (14.2%) was rare among small children and increased in 10-40 years patients. The BCR/ABL1 rearrangement increased progressively with age, starting from the 10-14 cohort and impacting for 52.7% of cases in the 6th decade. Similarly, the MLL/AF4 rearrangement constantly increased up to the 5th decade, while the ETV6/RUNX1 rearrangement disappeared from the age of 30 onwards. This study shows that adolescents and young adults are characterized by a male prevalence, greater T-lineage acute lymphoblastic leuekmia percentage, an increase of poor prognostic molecular markers with aging compared to children, and conclusively quantifies the progressive increase with age of BCR/ABL+ patients, potentially manageable by targeted therapies.

Published
2013

30. RISK-ADAPTED, MRD-DIRECTED THERAPY FOR YOUNG ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: RESULTS OF THE AML1310 TRIAL OF THE GIMEMA GROUP

Author

Venditti, A, Piciocchi, A, Candoni, A, Melillo, L, Calafiore, V, Cairoli, R, De Fabritiis, P, Storti, G, Salutari, P, Lanza, F, Martinelli, G, Luppi, M, Mazza, P, Falini, B, Cuneo, A, Specchia, G, Fabbiano, F, Tafuri, A, Ronci, B, Tieghi, A, Fracchiolla, N, Capelli, D, Foa, R, Ronco, F, La Sala, E, Fazi, P, Maurillo, L, Buccisano, F, Del Principe, M, Lo Coco, F, Arcese, W, Amadori, S, Fracchiolla, NS, Del Principe, MI, Venditti, A, Piciocchi, A, Candoni, A, Melillo, L, Calafiore, V, Cairoli, R, De Fabritiis, P, Storti, G, Salutari, P, Lanza, F, Martinelli, G, Luppi, M, Mazza, P, Falini, B, Cuneo, A, Specchia, G, Fabbiano, F, Tafuri, A, Ronci, B, Tieghi, A, Fracchiolla, N, Capelli, D, Foa, R, Ronco, F, La Sala, E, Fazi, P, Maurillo, L, Buccisano, F, Del Principe, M, Lo Coco, F, Arcese, W, Amadori, S, Fracchiolla, NS, and Del Principe, MI

Published
2017

31. ABSOLUTE LYMPHOCYTE COUNT IS NOT A PREDICTOR FOR SURVIVAL IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA. FINAL RESULTS OF A MULTICENTER STUDY

Author

SACCULLO, Giorgia, MANCUSO, Salvatrice, ABBADESSA, Vincenzo, SIRAGUSA, Sergio, Bono, R, Branca, A, Cangialosi, C, Raso, S, Quintini, G, Lipari, MG, Fabbiano, F, Specchia, G, Di Raimondo, F, Saccullo, G, Bono, R, Branca, A, Cangialosi, C, Mancuso, S, Raso, S, Quintini, G, Lipari, MG, Fabbiano, F, Abbadessa, V, Specchia, G, Di Raimondo, F, and Siragusa, S

Subjects
multiple myeoloma, lymphocite count, prognostic factors, Settore MED/15 - Malattie Del Sangue
Published
2012

32. ABSOLUTE LYMPHOCYTE COUNT IS NOT A PREDICTOR FOR SURVIVAL IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA

Author

Saccullo, G, Bono, R, Branca, A, Cangialosi, C, Raso, S, Quintini, G, Lipari, M, Fabbiano, F, Specchia, G, Di Raimondo, F, MANCUSO, Salvatrice, ABBADESSA, Vincenzo, SIRAGUSA, Sergio, Saccullo, G, Bono, R, Branca, A, Cangialosi, C, Mancuso, S, Raso, S, Quintini, G, Lipari, M, Fabbiano, F, Abbadessa, V, Specchia, G, Di Raimondo, F, and Siragusa, S

Subjects
multiple myeloma, lymphocyte count
Published
2012

33. ABSOLUTE LYMPHOCYTE COUNT AS PREDICTOR FOR SURVIVAL IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA

Author

SACCULLO, Giorgia, MANCUSO, Salvatrice, CASUCCIO, Alessandra, ABBADESSA, Vincenzo, SIRAGUSA, Sergio, Raso, S, Branca, A, Cangialosi, C, Bono, R, Quintini, G, Lipari, MG, Augello, A, Fabbiano, F, Di Raimondo, F, Saccullo, G, Raso, S, Branca, A, Cangialosi, C, Bono, R, Quintini, G, Lipari, MG, Mancuso, S, Augello, A, Casuccio, A, Fabbiano, F, Abbadessa, V, Di Raimondo, F, and Siragusa, S

Subjects
multiple myeloma, Settore MED/15 - Malattie Del Sangue
Published
2011

34. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib

Author

Castagnetti, F, Gugliotta, G., Breccia, M., Stagno, F., Iurlo, A., Albano, F., Abruzzese, E., Martino, B., Levato, L., Intermesoli, T., Pregno, P., Rossi, G., Gherlinzoni, F., Leoni, P., Cavazzini, F., Venturi, C., Soverini, S., Testoni, N., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., Rosti, G., Baccarani, M., on behalf of the GIMEMA CML Working Party (Lucarelli, G., Polimeno, G., Ladetto, M., Pini, M., Rupoli, S., Scortechini, A. R., Galieni, P., Bigazzi, C., Cantore, N., Palmieri, F., Specchia, G., Russo, Rossi., Rambaldi, A., Ferrari, M. L., Palandri, F., Luatti, S., Iacobucci, I., Bochicchio, M. T., Apolinari, M., Fogli, M., Cervello, I., Capucci, A., Giuliani, G., Malpignano, A., Girasoli, M., Angelucci, E., Usala, E., De Biasi, E., Tagariello, G., Sartori, R., Di Raimondo, F., Vigneri, P., Molica, S., Lentini, M., Lanza, F., Viganò, C., Grasso, M., Rapezzi, D., Cuneo, A., Ciccone, M., Bosi, A., Gozzini, A., Gobbi, M., Pierri, I., Chianese, R., De Blasio, A., Ciccone, F., Capochiani, E., Pelosini, M., Musolino, C., Russo, S., Cortelezzi, A., Luppi, M., Marasca, R., Pogliani, E. M., Gambacorti-Passerini, C., Luciano, L., Izzo, B., Ferrara, F., Annunziata, M., Mettivier, V., Sessa, U., Latte, G., Noli, D., Rege-Cambrin, G., Fava, C., Semenzato, G., Binotto, G., Fabbiano, F., Turri, D., Siragusa, S., Caracciolo, C., Musso, M., Porretto, F., Cazzola, M., Orlandi, E., Falini, B., Falzetti, F., Visani, G., Isidor, I., Di Bartolomeo, P., Di Lorenzo, R., Vallisa, D., Trabacch, I., Pizzuti, M., Zuffa, E., Salvucci, M., Ronco, F., Lelo, D., Merli, F., Avanzini, P., Tosi, P., Merli, A., Sica, S., Sorà, F., Latagliata, R., De Fabritiis, P., Trawiska, M., Amadori, S., Cantonetti, M., Majolino, I., Pacilli, L., Ronci, B., Cedrone, M., Mengarelli, A., Romano, A., Tafuri, A., Montefusc, O., Iuliano, F., Infusino, S., Dore, F., Fozza, C., Bocchia, M., Defina, M., Liberati, Am., Luzi, D., Boccadoro, M., Ferrero, D., Vitolo, U., Nicolosi, M., Gottardi, M., Calistri, E., Fanin, R., Tiribelli, M., Pizzolo, G., Bonifacio, M., Rodeghiero, F., Di Bona, E. )., Castagnetti, F, Gugliotta, G., Breccia, M., Stagno, F., Iurlo, A., Albano, F., Abruzzese, E., Martino, B., Levato, L., Intermesoli, T., Pregno, P., Rossi, G., Gherlinzoni, F., Leoni, P., Cavazzini, F., Venturi, C., Soverini, S., Testoni, N., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., Rosti, G., Baccarani, M., and on behalf of the GIMEMA CML Working Party [, Palandri F.], Pane, Fabrizio, Gugliotta, G, Breccia, M, Stagno, F, Iurlo, A, Albano, F, Abruzzese, E, Martino, B, Levato, L, Intermesoli, T, Pregno, P, Rossi, G, Gherlinzoni, F, Leoni, P, Cavazzini, F, Venturi, C, Soverini, S, Testoni, N, Alimena, G, Cavo, M, Martinelli, G, Pane, F, Saglio, G, Rosti, G, Baccarani, M, and GAMBACORTI PASSERINI, C

Subjects
DIAGNOSED CHRONIC-PHASE, Oncology, Male, Cancer Research, Time Factors, bcr-abl, Fusion Proteins, bcr-abl, Antineoplastic Agent, Hematology, Anesthesiology and Pain Medicine, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Cumulative incidence, Young adult, Chronic, Aged, 80 and over, Leukemia, PATIENTS RECEIVING IMATINIB, CHRONIC MYELOGENOUS LEUKEMIA, TYROSINE KINASE INHIBITORS, BCR-ABL1 TRANSCRIPT LEVELS, EARLY MOLECULAR RESPONSE, CML WORKING PARTY, 3-YEAR FOLLOW-UP, EUROPEAN LEUKEMIANET, 400 MG, Myeloid leukemia, Middle Aged, Prognosis, Treatment Outcome, Retreatment, Imatinib Mesylate, Female, Tyrosine kinase, Human, medicine.drug, Adult, medicine.medical_specialty, Time Factor, Adolescent, Prognosi, Protein Kinase Inhibitor, Socio-culturale, Antineoplastic Agents, Treatment results, Follow-Up Studie, Young Adult, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Internal medicine, medicine, Humans, Protein Kinase Inhibitors, Aged, Antineoplastic Combined Chemotherapy Protocol, business.industry, Fusion Proteins, Imatinib, Follow-Up Studies, Surgery, Imatinib mesylate, BCR-ABL Positive, business, Myelogenous
Abstract

For almost 10 years imatinib has been the therapeutic standard of chronic myeloid leukemia. The introduction of other tyrosine kinase inhibitors (TKIs) raised a debate on treatment optimization. The debate is still heated: some studies have protocol restrictions or limited follow-up; in other studies, some relevant data are missing. The aim of this report is to provide a comprehensive, long-term, intention-to-treat, analysis of 559 newly diagnosed, chronic-phase, patients treated frontline with imatinib. With a minimum follow-up of 66 months, 65% of patients were still on imatinib, 19% were on alternative treatment, 12% died and 4% were lost to follow-up. The prognostic value of BCR-ABL1 ratio at 3 months (⩽10% in 81% of patients) was confirmed. The prognostic value of complete cytogenetic response and major molecular response at 1 year was confirmed. The 6-year overall survival was 89%, but as 50% of deaths occurred in remission, the 6-year cumulative incidence of leukemia-related death was 5%. The long-term outcome of first-line imatinib was excellent, also because of second-line treatment with other TKIs, but all responses and outcomes were inferior in high-risk patients, suggesting that to optimize treatment results, a specific risk-adapted treatment is needed for such patients.

Published
2015

35. Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph plus Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification

Author

Chiaretti, S, Vitale, A, Elia, L, Fedullo, Al, Albino, S, Piciocchi, A, Fazi, P, DI RAIMONDO, Francesco, Fornaro, A, Fabbiano, F, D'Arco, Am, Martinelli, G, Ronco, F, Santoro, Le, Cascavilla, N, Galieni, P, Tedeschi, A, Sica, S, Di Renzo, N, Melpignano, A, Carella, Am, Ferrara, F, Vignetti, M, and Foa, R.

Published
2015

37. High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results

Author

Carella, Am, Bellei, Monica, Brice, P, Gisselbrecht, C, Visani, G, Colombat, P, Fabbiano, F, Donelli, A, Luminari, Stefano, Feugier, P, Browett, P, Hagberg, H, and Federico, Massimo

Subjects
Time Factors, Dose-Response Relationship, Drug, Antineoplastic Agents, Hematology, Hodgkin Disease, Disease-Free Survival, Survival Rate, Advanced Hodgkin's Lymphoma, Humans, Transplantation, Homologous, High-dose therapy, Conventional therapy, Letters to the Editor, Follow-Up Studies, Neoplasm Staging, Stem Cell Transplantation
Published
2009
Full Text
View/download PDF

38. MULTI-GENOTYPING OF MINOR HISTOCOMPATIBILITY ANTIGENS (MHAGS) IN ALLOGENEIC STEM CELL TRANSPLANTATION AND THEIR ROLE IN DETERMINING GRAFT VERSUS HOST DISEASE (GVHD) AND GRAFT VERSUS LEUKEMIA (GVL) EFFECT

Author

Cattina, F., Skert, C., Bernardi, S., Malagola, Michele, Ottaviani, E., Bochicchio, M. T., Iacobucci, I., Soverini, S., Bonifazi, F., Bandini, G., Arpinati, M., Motta, M. R., Toffoletti, E., Damiani, D., Santoro, A., Fabbiano, F., Pastore, D., Specchia, G., Console, G., Bruno, M., Carella, G., Malagoli, A., Guadagnuolo, V., De Benedittis, C., Bergonzi, C., Fili, C., Turra, A., Ribolla, R., Cancelli, V., Alghisi, E., Perucca, Simone, DI PALMA, Andrea, Martinelli, G., and Russo, Domenico

Published
2014

39. Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres

Author

Pagano, L., Fianchi, L., Mele, L., Girmenia, C., Offidani, M., Ricci, P, Mitra, M. E., Picardi, M., Caramatti, C., Piccaluga, P., Nosari, A., Buelli, M., Allione, B., Cortelezzi, A., Fabbiano, F., Milone, G., Invernizzi, R., Martino, B., Masini, L., Todeschini, G., Cappucci, M. A., Russo, Domenico, Corvatta, L., Martino, P., Del Favero, A., Pagano, L, Fianchi, L, Mele, L, Girmenia, C, Offidani, M, Ricci, P, Mitra, Me, Picardi, Marco, Caramatti, C, Piccaluga, P, Nosari, A, Buelli, M, Allione, B, Cortelezzi, A, Fabbiano, F, Milone, G, Invernizzi, R, Martino, B, Masini, L, Todeschini, G, Cappucci, Ma, Russo, D, Corvatta, L, Martino, P, and Del Favero, A.

Subjects
Adult, Male, Adolescent, Immunocompromised Host, Anti-Infective Agents, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Trimethoprim, Sulfamethoxazole Drug Combination, Humans, Lung, Aged, Retrospective Studies, Lymphoma, Non-Hodgkin, Pneumonia, Pneumocystis, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Radiography, Treatment Outcome, Leukemia, Myeloid, Primary Myelofibrosis, Hematologic Neoplasms, Myelodysplastic Syndromes, Acute Disease, Multivariate Analysis, Thalassemia, Female, Multiple Myeloma, Bronchoalveolar Lavage Fluid
Abstract

A retrospective survey was conducted over a 10-year period (1990-99) among 52 haematology divisions in order to evaluate the clinical and laboratory characteristics and outcome of patients with proven Pneumocystis carinii pneumonia (PCP) complicating haematological diseases. The study included 55 patients (18 with non-Hodgkin's lymphoma, 10 with acute lymphoblastic leukaemia, eight with acute myeloid leukaemia, five with chronic myeloid leukaemia, four with chronic lymphocytic leukaemia, four with multiple myeloma, three with myelodys-plastic syndrome, two with myelofibrosis and one with thalassemia) who developed PCP. Among these, 18 (33%) underwent stem cell transplantation; only two received an oral prophylaxis with trimethroprim/sulphamethoxazole. Twelve patients (22%) developed PCP despite protective isolation in a laminar airflow room. The most frequent symptoms were: fever (86%), dyspnoea (78%), non-productive cough (71%), thoracic pain (14%) and chills (5%); a severe hypoxaemia was present in 39 patients (71%). Chest radiography or computerized tomography showed interstitial infiltrates in 34 patients (62%), alveolar infiltrates in 12 patients (22%), and alveolar-interstitial infiltrates in nine patients (16%). Bronchoalveolar lavage was diagnostic in 47/48 patients, induced sputum in 9/18 patients and lung biopsy in 3/8 patients. The diagnosis was made in two patients at autopsy. All patients except one started a specific treatment (52 patients trimethroprim/sulphamethoxazole, one pentamidine and one dapsone). Sixteen patients (29%) died of PCP within 30 d of diagnosis. Multivariate analysis showed that prolonged steroid treatment (P < 0.006) and a radiological picture of diffuse lung involvement (P < 0.003) were negative diagnostic factors.

Published
2002

40. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia

Author

Tafuri, Agostino, Gregorj, C, Petrucci, Mt, Ricciardi, Maria Rosaria, Mancini, M, Cimino, Giuseppe, Mecucci, C, Tedeschi, A, Fioritoni, G, Ferrara, F, DI RAIMONDO, F, Gallo, E, Liso, V, Fabbiano, F, Cascavilla, N, Pizzolo, G, Camera, A, Pane, F, Lanza, F, Cilloni, D, Annino, L, Vitale, A, Vegna, Ml, Vignetti, Marco, Foa, Roberto, Mandelli, Franco, ON BEHALF OF THE GIMEMA GROUP, Tafuri, A., Gregorj, C., Petrucci, M. T., Ricciardi, M. R., Mancini, M., Cimino, G., Mecucci, C., Tedeschi, A., Fioritoni, G., Ferrara, F., DI RAIMONDO, F., Gallo, E., Liso, V., Fabbiano, F., Cascavilla, N., Pizzolo, G., Camera, A., Pane, Fabrizio, Lanza, F., Cilloni, D., Annino, L., Vitale, A., Vegna, M. L., Vignetti, M., Foa, R., and Mandelli, F.

Subjects
Male, medicine.medical_treatment, physiological processes, Biochemistry, Gastroenterology, Gene expression, polycyclic compounds, Prospective Studies, Prospective cohort study, P-glycoprotein, Univariate analysis, biology, GIMEMA ALL0496 protocol, adult, Remission Induction, Hematology, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Flow Cytometry, Prognosis, Treatment Outcome, Female, multiple drug resistance (MDR1), multiple drug resistance (MDR1), protein expression, independent predictor of complete remission, adult, acute lymphoblastic leukemia,GIMEMA ALL0496 protocol, medicine.medical_specialty, Adolescent, Immunology, Bone Marrow Cells, Context (language use), acute lymphoblastic leukemia, NO, Acute lymphocytic leukemia, Internal medicine, medicine, Humans, ATP Binding Cassette Transporter, Subfamily B, Member 1, neoplasms, protein expression, Analysis of Variance, Chemotherapy, Blood Cells, business.industry, independent predictor of complete remission, Cell Biology, medicine.disease, biology.protein, Adult Acute Lymphoblastic Leukemia, Blast Crisis, business, ACUTE MYELOID-LEUKEMIA, P-GLYCOPROTEIN EXPRESSION, MULTIDRUG-RESISTANCE MDR1, Biomarkers
Abstract

Little is known about the prognostic role of multidrug resistance (MDR) in adults with newly diagnosed acute lymphoblastic leukemia (ALL). In the context of the GIMEMA ALL0496 protocol, we evaluated the impact of MDR1 (protein expression and function) on the achievement of complete remission (CR) and clinical outcome. Flow cytometric analysis of MDR1 expression (D) and function (rhodamine-123 efflux) was obtained in 203 and 158 patients, respectively. MDR1 expression was detected in 44 (21.7%) of 203 patients, and function was found in 23 (14.6%) of 158 (14.6%) patients. Expression of the multidrug resistance-associated protein 1 (MRP1) and lung-resistance protein (LRP) evaluated in 43 samples was found in 13 and 26 patients, respectively. Among the 200 patients evaluable for the clinical correlation study, 125 (79.6%) of 157 without MDR1 expression achieved CR compared with 23 (53.5%) of 43 with MDR1 expression (P =.001). At univariate analysis, MDR1 expression was significantly associated with CR when considered as a dichotomized (P =.001) or continuous (P =.01) variable. At multivariate analysis, dichotomized evaluation of MDR1 expression independently predicted CR (P =.004) with age (P =.03) and CD34 (P =.03); as a continuous variable, MDR1 expression (P =.03) was the only significant factor other than CD34 (P =.01). MDR1 function failed to predict achievement of CR or of MRP1 and LRP expression. MDR1 expression did not correlate with CR duration, nor did it predict for survival duration. These results demonstrate that MDR1 expression in de novo adult ALL is an independent predictor of CR achievement.

Published
2002

41. MULTI-GENOTYPE OF MINOR HISTOCOMPATIBILITY ANTIGENS (MHAGS) TO STUDY GRAFT VERSUS HOST DISEASE (GVHD) AND GRAFT VERSUS LEUKEMIA (GVL) EFFECTS IN ALLOGENEIC STEM CELL TRANSPLANTATION

Author

Cattina, F., Skert, C., Bernardi, S., Ottaviani, E., Bochicchio, M., Iacobucci, I., Soverini, S., Bonifazi, F., Arpinati, M., Motta, M., Toffoletti, E., Damiani, D., Armando Santoro, Fabbiano, F., Pastore, D., Specchia, G., Console, G., Martino, B., Guadagnuolo, V., Benedittis, C., Malagola, M., Bergonzi, C., Fili, C., Turra, A., Ribolla, R., Cancelli, V., Alghisi, E., Perucca, S., Di Palma, A., Martinelli, G., and Russo, D.

Published
2013

42. Differences among young adults, adults and elderly chronic myeloid leukemia patients

Author

Castagnetti, F, Gugliotta, G, Baccarani, M, Breccia, M, Specchia, G, Levato, L, Abruzzese, E, Rossi, G, Iurlo, A, Martino, B, Pregno, P, Stagno, F, Cuneo, A, Bonifacio, M, Gobbi, M, Russo, D, Gozzini, A, Tiribelli, M, De Vivo, A, Alimena, G, Cavo, M, Martinelli, G, Pane, F, Saglio, G, Rosti, G, Salvi, F, Pini, M, Leoni, P, Rupoli, S, Galieni, P, Bigazzi, C, Cantore, N, Palmieri, F, Albano, F, Russo Rossi, A, Rambaldi, A, Intermesoli, T, Palandri, F, Testoni, N, Luatti, S, Soverini, S, Iacobucci, I, Bochicchio, M, Apolinari, M, Fogli, M, Cervello, I, Capucci, A, Malagola, M, Malpignano, A, Girasoli, M, Angelucci, E, Usala, E, Storti, S, De Biasi, E, Tagariello, G, Sartori, R, Di Raimondo, F, Vigneri, P, Impera, S, Molica, S, Lanza, F, Viganò, C, Grasso, M, Rapezzi, D, Cavazzini, F, Bosi, A, Santini, V, Capalbo, S, Spinosa, G, Pierri, I, Bergamaschi, M, Carella, A, Bacigalupo, A, De Blasio, A, Ciccone, F, Di Renzo, N, Musolino, C, Russo, S, Cortelezzi, A, Morra, E, Pungolino, E, Luppi, M, Marasca, R, Pogliani, E, GAMBACORTI PASSERINI, C, Luciano, L, Ferrara, F, Annunziata, M, Latte, G, Noli, D, Rege Cambrin, G, Fava, C, Semenzato, G, Binotto, G, Fabbiano, F, Turri, D, Siragusa, S, Caracciolo, C, Musso, M, Porretto, F, Aversa, F, Crugnola, M, Cazzola, M, Orlandi, E, Falini, B, Falzetti, F, Visani, G, Isidori, A, Fioritoni, G, Di Lorenzo, R, Vallisa, D, Trabacchi, E, Petrini, M, Galimberti, S, Pizzuti, M, Zaccaria, A, Salvucci, M, Ronco, F, Ielo, D, Merli, F, Avanzini, P, Tosi, P, Merli, A, Musto, P, De Stefano, V, Sica, S, Latagliata, R, De Fabritiis, P, Trawiska, M, Majolino, I, Pacilli, L, Ronci, B, Cedrone, M, Petti, M, Pisani, F, Tafuri, A, Montefusco, E, Iuliano, F, Dore, F, Pardini, S, Bocchia, M, Defina, M, Liberati, A, Luzzi, D, Boccadoro, M, Ferrero, D, Vitolo, U, Gherlinzoni, F, Calistri, E, Fanin, R, Pizzolo, G, Meneghini, V, Rodighiero, F, D'Emilio, A, GAMBACORTI PASSERINI, CARLO, D'Emilio, A., Castagnetti, F, Gugliotta, G, Baccarani, M, Breccia, M, Specchia, G, Levato, L, Abruzzese, E, Rossi, G, Iurlo, A, Martino, B, Pregno, P, Stagno, F, Cuneo, A, Bonifacio, M, Gobbi, M, Russo, D, Gozzini, A, Tiribelli, M, De Vivo, A, Alimena, G, Cavo, M, Martinelli, G, Pane, F, Saglio, G, Rosti, G, Salvi, F, Pini, M, Leoni, P, Rupoli, S, Galieni, P, Bigazzi, C, Cantore, N, Palmieri, F, Albano, F, Russo Rossi, A, Rambaldi, A, Intermesoli, T, Palandri, F, Testoni, N, Luatti, S, Soverini, S, Iacobucci, I, Bochicchio, M, Apolinari, M, Fogli, M, Cervello, I, Capucci, A, Malagola, M, Malpignano, A, Girasoli, M, Angelucci, E, Usala, E, Storti, S, De Biasi, E, Tagariello, G, Sartori, R, Di Raimondo, F, Vigneri, P, Impera, S, Molica, S, Lanza, F, Viganò, C, Grasso, M, Rapezzi, D, Cavazzini, F, Bosi, A, Santini, V, Capalbo, S, Spinosa, G, Pierri, I, Bergamaschi, M, Carella, A, Bacigalupo, A, De Blasio, A, Ciccone, F, Di Renzo, N, Musolino, C, Russo, S, Cortelezzi, A, Morra, E, Pungolino, E, Luppi, M, Marasca, R, Pogliani, E, GAMBACORTI PASSERINI, C, Luciano, L, Ferrara, F, Annunziata, M, Latte, G, Noli, D, Rege Cambrin, G, Fava, C, Semenzato, G, Binotto, G, Fabbiano, F, Turri, D, Siragusa, S, Caracciolo, C, Musso, M, Porretto, F, Aversa, F, Crugnola, M, Cazzola, M, Orlandi, E, Falini, B, Falzetti, F, Visani, G, Isidori, A, Fioritoni, G, Di Lorenzo, R, Vallisa, D, Trabacchi, E, Petrini, M, Galimberti, S, Pizzuti, M, Zaccaria, A, Salvucci, M, Ronco, F, Ielo, D, Merli, F, Avanzini, P, Tosi, P, Merli, A, Musto, P, De Stefano, V, Sica, S, Latagliata, R, De Fabritiis, P, Trawiska, M, Majolino, I, Pacilli, L, Ronci, B, Cedrone, M, Petti, M, Pisani, F, Tafuri, A, Montefusco, E, Iuliano, F, Dore, F, Pardini, S, Bocchia, M, Defina, M, Liberati, A, Luzzi, D, Boccadoro, M, Ferrero, D, Vitolo, U, Gherlinzoni, F, Calistri, E, Fanin, R, Pizzolo, G, Meneghini, V, Rodighiero, F, D'Emilio, A, GAMBACORTI PASSERINI, CARLO, and D'Emilio, A.

Abstract

Background: The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear how the characteristics of the disease vary with age. In children, where CML is very rare, it presents with more aggressive features, including huge splenomegaly, higher cell count and higher blast cell percentage. Patients and methods: To investigate if after childhood the disease maintains or loses these characteristics of aggressiveness, we analyzed 2784 adult patients, at least 18 years old, registered by GIMEMA CMLWP over a 40-year period. Results: Young adults (YAs: 18-29 years old) significantly differed from adults (30-59 years old) and elderly patients (at least 60 years old) particularly for the frequency of splenomegaly (71%, 63% and 55%, P < 0.001), and the greater spleen size (median value: 4.5, 3.0 and 1.0 cm, P < 0.001). According to the EUTOS score, that is age-independent, high-risk patients were more frequent among YAs, than among adult and elderly patients (18%, 9% and 6%, P < 0.001). In tyrosine kinase inhibitors-treated patients, the rates of complete cytogenetic and major molecular response were lower in YAs, and the probability of transformation was higher (16%, 5% and 7%, P = 0.011). Conclusions: The characteristics of CML or the host response to leukemia differ with age. The knowledge of these differences and of their causes may help to refine the treatment and to improve the outcome.

Published
2015

43. A SIMPLE CLINICAL PROGNOSTIC SCORING SYSTEM FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKAEMIA PATIENTS WITH NORMAL KARYOTYPE: A RETROSPECTIVE ANALYSIS ON 530 CASES

Author

Malagola, Michele, Skert, C, Vignetti, M, Piciocchi, A, Martinelli, G, Clavio, M, Gobbi, M, Candoni, A, Damiani, D, Bocchia, M, Lauria, F, Zaccaria, A, Mazza, P, Visani, G, Peli, A, Mancini, M, Foà, R, Martelli, M, Cantore, N, Caraci, Mr, Petrini, M, De Fabritiis, P, Fioritoni, G, Nobile, F, Fabbiano, F, Pastore, D, Specchia, G, Baccarani, M, Lo Coco, F, Amadori, S, Mandelli, F, and Russo, Domenico

Published
2010

44. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

Author

LO COCO, F, Avvisati, G, Vignetti, M, Breccia, M, Gallo, E, Rambaldi, A, Paoloni, F, Fioritoni, G, Ferrara, F, Specchia, G, Cimino, G, Diverio, D, Borlenghi, E, Martinelli, G, DI RAIMONDO, Francesco, DI BONA, E, Fazi, P, Peta, A, Bosi, A, Carella, Am, Fabbiano, F, Pogliani, Em, Petti, Mc, Amadori, S, Mandelli, F, and ITALIAN GIMEMA COOPERATIVE GROUP

Published
2010

47. High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SD-AraC) during Induction and Value of IL-2 during Maintenance in Acute Myelogenous Leukemia (AML): Impact of AraC Dose on Complete Remission Rate and Toxicity (Results on the first 1700 randomized patients of the AML-12 trial of EORTC and GIMEMA Leukemia Groups)

Author

Willemze, R., Suciu, S., Mandelli, F., Labar, B., Marie, Mistrik, Jp, Liso, V., Fabbiano, F., Nobile, F., Sborgia, M., Rotoli, B., Selleslag, Dld, Lefrere, F., Peta, A., Martelli, Maurizio, Leone, G., Cantore, N., Beksac, M., Zwi, B., Thomas, X., Greco, Mm, Bron, D, Fillet, G., Guimaraes, Je, Muus, P., Fazi, P., Baila, L., Vignetti, Marco, Amadori, M., de Witte, T., and Meloni, Giovanna

Published
2008

48. ERK1/2 phosphorylation in adult acute lymphoblastic leukemia patients: prognostic role and in vitro effects of MEK inhibition

Author

Gregorj, C, Ricciardi, Maria Rosaria, Petrucci, Mt, Scerpa, Mc, De Cave, F, Fazi, P, Vitale, A, Mancini, M, Cimino, Giuseppe, Palmieri, S, Di Raimondo, F, Specchia, G, Fabbiano, F, Cantore, N, Mosna, F, Camera, A, Luppi, M, Annino, L, Miraglia, E, Fioritoni, G, Ronco, F, Meloni, G, Andreeff, M, Milella, M, Mandelli, Franco, Foà, R, and Tafuri, Agostino

Published
2006

49. High levels of tumor load reduction after intensive chemotherapy favorably affect the prognosis of BCR/ABL plus ALL Adult patients receiving imatinib mesylate alone as a post-consolidation treatment according to the Italian GIMEMA LAL 0201/A protocol

Author

Cimino, Giuseppe, Elia, L., Pane, F., Vignetti, Marco, Fazi, P., Iacobelli, S., Meloni, Giovanna, Vitale, A., Martini, V., Martinelli, G., Di Raimondo, F., Bonifacio, M., Fabbiano, F., Saglio, G., Baccarani, M., Foa, R., and Mandelli, F.

Published
2006

50. BREAST CANCER RESISTANCE PROTEIN (BCRP) EXPRESSION AFFECT EVENT-FREE SURVIVAL IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

Author

Gregorj, C, DE CAVE, Fabiana, Petrucci, Mt, Ricciardi, Maria Rosaria, Scerpa, Mc, Vignetti, M, Vitale, A, Meloni, G, Liso, V, Di Raimondo, F, Ferrara, F, Fabbiano, F, Camera, A, Fioritoni, G, Miraglia, E, Annino, L, Cascavilla, N, Marmont, F, Mazza, P, Perbellini, O, Cartore, N, Luppi, M, Nobile, F, Sica, S, Salvi, F, Mandelli, Franco, Foà, R., and Tafuri, Agostino

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results